Mouse Proteomics-SIP Experiment (OSU and OU)
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Mus Musculus (mouse)
TISSUE(S): Colon, Feces
SUBMITTER: 
sadie grant
LAB HEAD: Ryan Sean Mueller
PROVIDER: PXD080386 | Pride | 2026-08-07
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| PanC_20250715_02_DDA_01.raw | Raw | |||
| PanC_20250715_02_DDA_02.raw | Raw | |||
| PanC_20250715_02_DDA_03.raw | Raw | |||
| PanC_20250715_02_DDA_07_rep2.raw | Raw | |||
| PanC_20250715_02_DDA_08_rep2.raw | Raw |
Items per page: 5 1 - 5 of 50 |
Similar Datasets
Project description:We used TMT labelling to set up different experiment channels containing mixtures of the host cell carrier proteome (E coli) and mock biotherapeutic (BSA), to compare with interference detection channel to model and filter interference, a phenomenon where host cell proteins (HCPs) co-elute with high-background biotherapeutic during LC-MS monitoring of QC during biomanufacture of biopharmaceuticals. Our work overcomes limitations of ELISA and pre-tryptic digest procedures to produce a reproducible method using TMT labels to identify and quantify a range of HCPs in one experiment.
2026-01-12 | PXD049970 | Pride
Project description:See metadata.xlsx for detailPan_062822_X1iso5.raw1%_13C_unlabeled_EcoliPan_062822_X2iso5.raw1%_13C_unlabeled_EcoliPan_062822_X3iso5.raw1%_13C_unlabeledEcoliPan_062822_X5.raw2%_13C_labeled_EcoliPan_062822_X6.raw2%_13C_labeled_EcoliPan_062822_X7.raw2%_13C_labeled_EcoliPan_062822_X19.raw5%_13C_labeled_EcoliPan_062822_X21.raw5%_13C_labeled_EcoliPanC_092822_X32.raw5%_13C_labeled_EcoliPan_052322_X09.raw25%_13C_labeled_EcoliPan_052322_X10.raw25%_13C_labeled_EcoliPan_052322_X11.raw25%_13C_labeled_EcoliPan_052322_X13.raw50%_13C_labeled_EcoliPan_052322_X13_iso08.raw50%_13C_labeled_Ecoli_0.8_Da_Isolation_WindowPan_052322_X13_iso15.raw50%_13C_labeled_Ecoli_1.5_Da_Isolation_WindowPan_052322_X14.raw50%_13C_labeled_EcoliPan_052322_X14_iso03.raw50%_13C_labeled_Ecoli_3_Da_Isolation_WindowPan_052322_X14_iso07.raw50%_13C_labeled_Ecoli_7_Da_Isolation_WindowPan_052322_X15.raw50%_13C_labeled_EcoliPanC_102522_X46.raw99%_13C_labeled_EcoliPanC_102522_X47.raw99%_13C_labeled_EcoliPanC_102522_X48.raw99%_13C_labeled_Ecoli
2024-06-14 | PXD041414 | Pride
Project description:BACKGROUND & AIMS: The immune system comprises an innate and an adaptive immune response to combat pathogenic agents. The human enteropathogen Salmonella enterica serovar Typhimurium invades the intestinal mucosa and triggers an early innate pro-inflammatory host gene response, which results in diarrheal disease. Several host factors are involved in the acute early response to Salmonella infection. Transcription factors and transcription co-regulators have an especially important function, because they are required for the expression and synthesis of pro-inflammatory cytokines, chemokines and adhesion molecules. A central transcription factor involved in inflammation is NF-κB, which requires the nuclear protein PARP1 as co-factor for the expression of some of its target genes. Here, we investigated the role of PARP1 during Salmonella infection using a mouse model for Salmonella-induced colitis. METHODS: To study enterocolitis by Salmonella Typhimurium, an established mouse model system, which relies on streptomycin-pretreatment prior to Salmonella infection, was employed. Histopathologic signs of inflammation and cecum colonization at various time-points after infection of wild type and PARP1 knockout mice were analyzed. PARP1 expression in the gut mucosa was studied by quantitative RT-PCR, Western blot and immunofluorescence. Gene expression profiles of infected and control infected mice in the wild type or PARP1 knockout background were obtained by whole mouse genome arrays and confirmed by quantitative RT-PCR. 2 genotypes (wildtype, PARP1 knockout), 2 treatments (Salmonella SB300 infection, Salmonella SB161 control infection), 2 time-points (6h, 10h). 2-3 replicates/condition.
2010-05-27 | E-GEOD-19174 | biostudies-arrayexpress
Project description:The benefits of breastfeeding infants are well characterized, including those on the immune system. However, determining the mechanism by which human breast milk (HBM) elicits effects on immune response requires investigation in an appropriate animal model. In the current study we used neonatal piglets and compared their gut microbiome using mass spectrometry based metaproteomics
2021-11-03 | PXD025432 | Pride
Project description:Cystatin D (CST5) is an inhibitor of several proteases of the cathepsin family that inhibits cell proliferation, migration and invasion of colon carcinoma cells. Some of these effects are unrelated to its antiprotease activity. Here, we use genome-wide expression microarrays to show that cystatin D regulates gene expression (including that of genes encoding transcription factors such as RUNX1, RUNX2, or MEF2C) in HCT116 cells. HCT116 colon adenocarcinoma cell lines stably expressing cystatin D (HCT116-CST5 clone 9 and clone 20), mock-transfected (HCT116-Mock) and un-transfected (HCT116-Untransfected) were generated as described (Ãlvarez-DÃaz et al., 2009, PUBMED:19662683) and genome-wide expression microarrays were obtained to achieve the gene expression profile induced by CST5.
2015-11-04 | E-GEOD-45904 | biostudies-arrayexpress
Project description:Here, we used reverse-phase liquid chromatography-coupled tandem mass spectrometry to study the pre-weaned lamb proteome and metaproteome in ten different gastrointestinal tracts: rumen, reticulum, omasum, abomasum, duodenum, jejunum, ileum, cecum, colon, and rectum.
2017-12-14 | PXD008192 | Pride
Project description:Most drugs used in the clinic and drug candidates target multiple proteins, and thus detailed characterization of their efficacy targets is required. While current methods rely on quantitative measurements at thermodynamic equilibrium, kinetic parameters such as the residence time of a drug on its target provide a better proxy for efficacy in vivo. Here, we present a new Residence Time Proteome Integral Solubility Alteration (ResT-PISA) assay which provides monitoring temporal protein solubility profiles after drug removal in either cell lysate or intact cells, quantifying the lifetime of the drug-target interaction. A compressed version of the assay measures the integral under the off-curve and enables the multiplexing of binding affinity proxy measurements with residence time assessment into a single proteomic analysis. We introduce a combined scoring system for three parametric dimensions to improve prioritization of targets. By providing complementary information to other characteristics of drug-target interaction, ResT-PISA approach can become a useful tool in drug development and precision medicine.
2023-01-06 | PXD034351 | Pride
Project description:In the DSS-induced colitis model, the epithelial damage and resulting inflammation is restricted to the colon, with a potential influence on the microbial composition in the adjacent cecum. Several studies have reported changes of the gut microbiota in the DSS-induced colitis model and other mouse models of IBD. Furthermore, metaproteomics analysis of the gut microbiome in a mouse model of Crohn’s disease demonstrated that disease severity and location are microbiota-dependent, with clear evidence for the causal role of bacterial dysbiosis in the development of chronic ileal inflammation. We have developed a refined model of chronic DSS-induced colitis that reflects typical symptoms of human IBD without a risky body weight loss usually observed in DSS models [Hoffmann et al., submitted]. In this study, we used metaproteomics to characterize the disease-related changes in bacterial protein abundance and function in the refined model of DSS-induced colitis. To assess the structural and functional changes, we applied 16S rRNA gene sequencing and metaproteomics analysis of the intestinal microbiota in three different entities of the intestinal environment, i.e. colon mucus, colon content and cecum content.
2020-03-17 | PXD007220 | Pride
Project description:Background: Sepsis-associated encephalopathy (SAE) is a common and severe complication of sepsis. While several studies have reported the proteomic alteration in plasma, urine, heart, etc. of sepsis, few research focused on the brain tissue. This study aims at discovering the differentially abundant proteins in the brains of septic rats to identify biomarkers of SAE. Methods: The Prague-Dawley rats were randomly divided into sepsis (n = 6) or sham (n = 6) groups, and then the whole brain tissue was dissected at 24 h after surgery for further protein identification by TMT-LC–MS/MS-based proteomics. Ingenuity pathway analysis, Gene ontology knowledgebase, and STRING database are used to explore the biological significance of proteins with altered concentration. Results: Among the total of 3163 proteins identified in the brain tissue, 57 were increased while 38 were decreased in the sepsis group compared to the sham group. Bioinformatic analyses suggest that the differentially abundant proteins are highly related to cellular microtubule metabolism, energy production, nucleic acid metabolism, neurological disease, etc. Additionally, acute phase response signaling was possibly activated and PI3K/AKT signaling was suppressed during sepsis. An interaction network established by IPA revealed that Akt1, Gc-globulin, and ApoA1 were the core proteins. The increase of Gc-globulin and the decrease of Akt1 were confirmed by Western blot. Conclusions: Based on the multifunction of these proteins in several brain diseases, we first propose that Gc-globulin, ApoA1, PI3K/AKT pathway, and acute phase response proteins (hemopexin and cluster of alpha-2-macroglobulin) can potentially be diagnosis biomarkers, therapeutic targets, and prognosis indicators of SAE. These results may provide new insights into the pathologic mechanism of SAE, yet further research is required to explore the functional implications and clinical applications of the differentially abundant proteins in the brains of sepsis group.
2023-03-10 | PXD035112 | Pride
Project description:Protein misfolding is a contributor to the development of type 2 diabetes (T2D), but it is unknown whether impaired proteostasis in T2D is generalized or has special features. Here, we report a robust accumulation of misfolded proteins within the mitochondria of human pancreatic islets from patients with T2D and elucidate its impact on β cell viability. Quantitative proteomics studies of protein aggregates surprisingly reveal that islets from donors with T2D have a signature more closely resembling mitochondrial rather than ER protein misfolding. Loss of the matrix protease LONP1, a vital component of the mitochondrial proteostatic machinery whose expression is reduced in β cells of donors with T2D, yields mitochondrial protein misfolding and reduced respiratory function, ultimately leading to β cell apoptosis and hyperglycemia. Intriguingly, LONP1 gain of function ameliorates mitochondrial protein misfolding and restores human β cell survival following glucolipotoxicity via a protease-independent effect requiring LONP1-mtHSP70 chaperone activity. Thus, LONP1 promotes β cell survival and prevents hyperglycemia by facilitating mitochondrial protein folding. These observations open novel insights into the nature of proteotoxicity that promotes β cell loss during the pathogenesis of T2D that could be considered as future therapeutic targets.
2025-06-05 | PXD060404 | Pride